Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

AbbVie (ABBV) Set To Report Q2 Earnings: What To Expect

By Zacks Investment ResearchStock MarketsJul 22, 2019 11:58PM ET
AbbVie (ABBV) Set To Report Q2 Earnings: What To Expect
By Zacks Investment Research   |  Jul 22, 2019 11:58PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

AbbVie (NYSE:ABBV) is set to release its Q2 earnings before market open on Friday. AbbVie stock has performed very poorly YTD, falling 26%.


AbbVie Inc. is an American biopharmaceutical company based in Illinois. AbbVie was established as a spin-off of Abbott Laboratories (NYSE:ABT) in 2013. AbbVie is the marketer and producer of Humira, the best-selling drug in the world. Humira is used to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and other issues related to these diseases.

AbbVie has also made a couple of acquisitions over the past couple of months. In June, AbbVie acquired Botox-producer Allergan (NYSE:AGN) plc for $63 billion. In July, AbbVie announced it would acquire Mavupharma, which would help bolster the company’s cancer drug pipeline.

Since the Allergan acquisition announcement, ABBV stock has fallen 13%. Currently, AbbVie shares are trading at 7.39 times earnings, which may make the stock seem undervalued compared to its industry’s average P/E of 14.37. However, ABBV’s lower P/E is most likely due to its falling stock price in recent months and may not be a good representation of the stock’s value.

Additionally, AbbVie is a solid dividend stock. Since November 2017, AbbVie has increased its dividend three times, the most recent being an 11% increase that came in February 2019. The annual dividend is currently at $4.28, which amounts to a dividend yield of about 6.2%.

Q2 Outlook & Earnings Trends

Revenues for Q2 are expected to fall 2% year-over-year from $8.28 billion to $8.10 billion, according to our Zacks Consensus Estimates. After years of year-over-year revenue growth, predictions suggest this will be the second quarter in a row of shrinking revenues.

In Q1, revenues fell 1.3% from Q1 2018. The primary source of the revenue decline was a decrease in international sales. International sales of Humira declined by nearly half a billion dollars, or over 25%. Humira accounts for over 50% of AbbVie’s revenue, so investors are clearly worried about the firm’s overreliance on the drug.

Our Zacks Key Company Metrics predict international Humira sales will slip by a similar amount again for Q2. While U.S. sales are expected to increase slightly, from $3.521 billion in Q2 2018 to $3.785 billion. But this growth is simply not enough to make up for the expected international revenue decrease from $1.664 billion to $1.028 billion. The decrease in international Humira sales is a result of competition in Europe.

Meanwhile, AbbVie’s earnings are expected to grow by 10.5%. The quarterly growth will help contribute to an expected fiscal 2019 growth of 11.5%, which would give fiscal EPS of $8.82 compared to $7.91 in 2018.

Bottom Line

Humira’s patent in the U.S. expired in 2016, but domestic competitors are not expected to hit the market until 2023 due to AbbVie’s strong and persistent litigation leading up to the patent expiration. Until then, AbbVie needs to continue to grow its portfolio and the addition of Botox was a big one as it can help make up for some of the revenue that will be lost to Humira competitors. The firm’s international competitors have already taken a large toll on AbbVie’s revenue. And the arrival of domestic competitors will most likely have an even more significant impact on the company.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>

AbbVie Inc. (ABBV): Free Stock Analysis Report

Original post

Zacks Investment Research
AbbVie (ABBV) Set To Report Q2 Earnings: What To Expect

Related Articles

AbbVie (ABBV) Set To Report Q2 Earnings: What To Expect

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email